Supported Activities
* indicates required field
Educational Grant Consideration for Supported Activities
GE Healthcare Pharmaceutical Diagnostics collaborates with the global healthcare community to address knowledge gaps and improve patient outcomes. Independent educational grants from GE Healthcare are available to support programs which are aligned with our medical and/or scientific strategies. GE Healthcare Pharmaceutical Diagnostics has no influence over any aspect of the educational programs and only ask for reports about the results and the impact of the programs.
Listed below are areas of interest that are aligned with our medical and/or scientific strategies and we encourage applicants to review these when applying. Due to budget parameters and educational goals of our Program this year, we encourage applicants to propose initiatives of modest cost, although all completed applications will be reviewed.
General Use of Diagnostic Imaging Agents:
- Selection of imaging agent choice and implications on operational workflow
- Expanding the clinical applications of contrast media and molecular imaging
- Health economic evaluations based upon the use of imaging agents
Contrast Media:
- Use of an automated syringeless technology and workflow efficiencies
- Workflow efficiencies to minimize exam preparation time and minimize contrast media waste
- Use and effects of macrocyclic versus linear contrast agents in contrast-enhanced MRI exams
- Identify selection criteria of contrast media agent and strategies to mitigate adverse events during contrast enhanced imaging
- Use of ultrasound enhancing agents in clinical decision making
- Optimize image quality when utilizing contrast media
Molecular Imaging:
- Novel application of PET imaging for metastatic breast cancer
- Quantitative analysis using molecular imaging agents
- Optimize image quality and reporting with dopamine transporter imaging
- Molecular Imaging as a biomarker of neurodegenerative diseases
- Incorporate quantification in dopamine transporter or amyloid imaging and impact on clinical interpretation
- PET or SPECT imaging of amyloid or dopamine transporters in the clinical diagnosis of dementias or Parkinsonian syndromes
|
|
|